<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719560</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG-377</org_study_id>
    <nct_id>NCT03719560</nct_id>
  </id_info>
  <brief_title>Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma</brief_title>
  <acronym>BrUOG-377</acronym>
  <official_title>Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 single-institution trial of early systemic central nervous system prophylaxis in
      high-risk diffuse large B-cell lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective phase 2 clinical trial of systemic central nervous system prophylaxis
      among patients with diffuse large B-cell lymphoma at high risk of central nervous system
      recurrence. The main objective is to evaluate safety and efficacy of early institution of
      intensive central nervous system prophylaxis in a high-risk group to minimize the risk of a
      devastating central nervous system recurrence. Patients receive standard primary
      immunochemotherapy with an addition of planned central nervous system prophylaxis courses on
      or around day 15 of cycles 2, 4, and 6. Growth factor support and Pneumocystis jirovecii
      prophylaxis is required. The primary endpoint of this pilot study is protocol-defined
      toxicity, whereas efficacy (cumulative incidence of central nervous system recurrence) will
      be a secondary endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of funding
  </why_stopped>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion with clinically significant toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Clinically significant toxicity as defined in the protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of central nervous system recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Cumulative incidence of central nervous system recurrence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CNS prophylaxis protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive central nervous system prophylaxis protocol using high-dose methotrexate and cytarabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Systemic methotrexate</description>
    <arm_group_label>CNS prophylaxis protocol</arm_group_label>
    <other_name>Methotrexate sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Systemic cytarabine</description>
    <arm_group_label>CNS prophylaxis protocol</arm_group_label>
    <other_name>Cytosar-U</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New diagnosis of diffuse large B-cell lymphoma, planned first-line therapy using the
             standard rituximab- and anthracycline-containing regimens

          -  No central nervous system involvement on initial staging

          -  Performance status of 0 or 1 (Eastern Cooperative Oncology Group scale)

          -  Renal function: creatinine clearance &gt;45 ml/min

          -  Not pregnant; agreeable to contraception

          -  Written informed consent

          -  High risk for central nervous system recurrence as determined by one of the following
             high-risk features:

               1. high central nervous system International Prognostic Index,

               2. testicular, breast, or uterine involvement,

               3. dual expresser or double/triple-hit status,

               4. HIV positive status, or

               5. Molecularly defined high-risk subtype.

        Exclusion Criteria:

          -  pregancy

          -  unable to provide informed consent

          -  significant comorbidity in the investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam J Olszewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roxanne Wood</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

